More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$34999527
EPS
-3.97
P/E ratio
--
Price to sales
105.1
Dividend yield
--
Beta
1.845693
Previous close
$0.31
Today's open
$0.30
Day's range
$0.28 - $0.31
52 week range
$0.28 - $19.11
show more
CEO
Jay Duker
Employees
214
Headquarters
Watertown, MA
Exchange
NASDAQ Global Market
Shares outstanding
113782597
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)---- $EYPT #EYPT--EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.
Business Wire • 2 hours ago

EyePoint, Inc. (EYPT) Presents at UBS Global Biopharma Conference 2026 Transcript
EyePoint, Inc. ( EYPT ) UBS Global Biopharma Conference 2026 November 17, 2026 3:40 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Conference Call Participants Alice Nettleton Presentation Alice Nettleton Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference.
Seeking Alpha • a day ago

EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
– Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis – – Strategic prioritization expected to generate $30 million in annualized savings – – $118 million in cash, cash equivalents and short-term investments, as of September 30, 2026 – WATERTOWN, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate developments.
GlobeNewsWire • Nov 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.
Zacks Investment Research • Nov 12, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:
GlobeNewsWire • Nov 6, 2026

EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m.
GlobeNewsWire • Nov 5, 2026

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money
GlobeNewsWire • Oct 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell EyePoint Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.